Kala's lead product shows promise in two eye indications
This article was originally published in Scrip
The Massachusetts-based ophthalmic company Kala Pharmaceuticals has reported positive data for its formulation of the steroid loteprednol etabonate KPI-121 in two indications, pain in cataract surgery and dry eye disease.
You may also be interested in...
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.
The third quarter could bring US approvals for a range of novel drugs, including the first treatment for a common eye disease, the first US approval of PD-1/L1 inhibitor from a Chinese firm, and the first oral therapy for postpartum depression.
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.